|Storage Temp:||Store at 8°C-20°C, protect from moisture and light|
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 receptor agonist used in individuals with type 2 diabetes as an addition to diet and exercise to improve glycemic control. Semaglutide is a GLP-1 mimic having 94% sequence homology to human GLP-1. It can bind to the GLP-1 receptor and activate the receptor to lower blood sugar by boosting insulin production and decreasing glucagon secretion as a GLP-1 receptor agonist. Furthermore, semaglutide can act on the digestive tract by delaying gastrointestinal emptying to induce fullness; on the brain by suppressing appetite; and on the circulatory system by repairing damaged intima and improving endothelial function.
How Does Semaglutide Work?
Semaglutide powder is an agonist of the glucagon-like peptide-1 receptor. It boosts the production of insulin, a hormone that reduces blood sugar levels, by imitating the effect of the incretin glucagon-like peptide-1 (GLP-1). It also appears to stimulate the proliferation of pancreatic beta cells, which are responsible for insulin generation and release. In addition, AASraw semaglutide has the ability to decrease glucagon production, a hormone that stimulates glycogenolysis (the release of stored carbs from the liver) and gluconeogenesis (the creation of new glucose). It reduces food intake by suppressing hunger and slows digestion in the stomach, which aids in weight loss. It suppresses appetite, food cravings, and fat storage.
The Research on Semaglutide
Semaglutide is a medication that was originally developed to treat diabetes. However, it has gained popularity as a weight loss drug after it was found to effectively help individuals lose weight, including the world’s second richest man, Elon Musk. Recently, the study—-Once-Weekly Semaglutide in Adolescents with Obesity—-published in the New England Journal of Medicine (NEJM) has found that semaglutide may also help obese adolescents reduce weight and promote heart health.
- Obese adolescents who took weekly semaglutide saw a 16.1% increase in body mass index (BMI) in an international phase 3a clinical trial, compared to a 0.6% increase in the placebo group.
- Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist that can reduce appetite, diet, and calorie intake, making it effective for weight loss.
- A large-scale clinical trial showed that semaglutide has an amazing effect as a weight loss medicine, with the treated group losing an average of 15.3 kg.
- In June 2021, the U.S. Food and Drug Administration (FDA) approved the marketing of semaglutide (Semaglutide), a weight-loss drug with a trade name of Wegovy.
- A recent study has found that semaglutide outperformed placebo in terms of weight loss and improvement of cardiometabolic risk factors in obese adolescents.
- After taking semaglutide, cardiovascular risk factors such as waist circumference, blood glucose index HbA1c, total cholesterol, low-density and very low-density lipoprotein cholesterol, triglycerides, and triglycerides improved.
- The semaglutide group outperformed the placebo group on weight-related quality-of-life measures, owing mostly to higher physical comfort scores.
Semaglutide has been shown to be an effective weight-loss medication, and recent research has demonstrated that it may also be beneficial for obese adolescents. While the medication is associated with some gastrointestinal side effects, it has been found to improve cardiovascular risk factors and quality of life measures.
Benefits of Using Semaglutide
Semaglutide is a versatile medication that offers a range of benefits for individuals with various medical conditions. Some of the most common conditions that can benefit from the use of AASraw Semaglutide include Type 2 Diabetes Mellitus, caidiovascular risks, obesity, and Alzheimer’s.
①Lowering Blood Glucose Levels
Semaglutide is a GLP-1 receptor agonist that is effective in lowering blood glucose levels in people with type 2 diabetes by several mechanisms. It stimulates insulin secretion, which helps to move glucose from the blood into the cells where it can be used for energy. Semaglutide also suppresses glucagon secretion, which reduces glucose production by the liver. Additionally, it slows down gastric emptying, which reduces the rate at which glucose enters the bloodstream after a meal.
In clinical trials,semaglutide has been shown to significantly reduce HbA1c levels, which is an indicator of long-term blood glucose control. In the SUSTAIN-1 trial,semaglutide reduced HbA1c levels by 1.5% compared to placebo, and in the SUSTAIN-10 trial, it reduced HbA1c levels by 1.8% compared to placebo. Semaglutide has also been shown to be effective in reducing fasting plasma glucose levels and postprandial glucose excursions.
②Reducing Risk of Cardiovascular Events
Semaglutide has been shown to reduce the risk of major adverse cardiovascular events (MACE) such as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes and established cardiovascular disease. This benefit was observed in the SUSTAIN-6 and PIONEER-6 trials, which showed a significant reduction in MACE with semaglutide treatment compared to placebo. Moreover, Semaglutide has been shown to improve several cardiovascular risk factors such as blood pressure, lipid profile, and markers of inflammation in people with type 2 diabetes. In the SUSTAIN-6 trial,semaglutide was associated with a significant reduction in systolic blood pressure and improvement in lipid profile, including reductions in total cholesterol, LDL cholesterol, and triglycerides.
Semaglutide is a potent weight loss agent, even in people without diabetes. Semaglutide works by reducing appetite and calorie intake, leading to a decrease in body weight. This is achieved through its effects on the central nervous system and the gastrointestinal tract. Semaglutide acts on the hypothalamus, which regulates hunger and satiety, and reduces the desire to eat by increasing feelings of fullness. Additionally, semaglutide slows down gastric emptying, which prolongs the feeling of fullness after a meal and reduces the urge to eat.
Clinical trials have demonstrated the weight loss benefits of semaglutide.In the STEP program, which evaluated the use of semaglutide for weight management in people without diabetes,semaglutide was associated with significant weight loss compared to placebo. Participants who received once-weekly semaglutide lost an average of 15% of their body weight over 68 weeks, while those who received a placebo lost only 2.4%.
In people with type 2 diabetes,semaglutide can lead to additional weight loss benefits. In the SUSTAIN 7 trial, which evaluated the efficacy and safety of semaglutide in people with type 2 diabetes,semaglutide was associated with a significant reduction in body weight compared to placebo. Participants who received semaglutide lost an average of 4.6 kg, while those who received a placebo lost only 1.2 kg.
④Treating Alzheimer’s Disease Symptom
Multiple preclinical studies have shown that semaglutide has neuroprotective properties against amyloid-β plaques in a human neuroblastoma (SH-SY5Y) cell line,suggesting that semaglutide can alleviate Alzheimer’s disease symptoms. Animal models have also shown that semaglutide has neuroprotective effects on animal models. According to Novo Nordisk’s announcement, the indication of semaglutide tablets for Alzheimer’s disease (AD) is in the clinical stage. Two global Phase III trials, EVOKE and EVOKE plus, are underway, and about 3,700 volunteers are expected to be recruited. This study compared with a placebo, evaluate the superiority of semaglutide tablets on cognitive function in subjects with mild cognitive impairment (MCI) or mild dementia caused by AD.
Precautions: It is key to purchase semaglutide from reputable sources, otherwise, you cannot get the best efficacy of semaglutide.As a professional semaglutide manufacturer and supplier, AASraw aims to supply pure semaglutide worldwide. If you have needs, AASraw’s semaglutide is a great choice for you.
The Side Effects of Semaglutide?
Semaglutide, like any medication, may cause side effects.
①Common side effects include:
- Abdominal pain
- Loss of appetite
②Less common but more serious side effects may include:
- Hypoglycemia (low blood sugar)
- Acute kidney injury
- Diabetic retinopathy complications
- Gallbladder disease
- Allergic reactions
- Thyroid tumors
Notes: The duration of side effects of semaglutide can vary depending on the individual and the severity of the side effects. In most cases, the side effects of semaglutide are temporary and will improve as your body adjusts to the medication. Common side effects such as nausea, diarrhea, vomiting, constipation, and headache typically resolve within a few days to a week. If you experience any unusual or severe side effects while taking semaglutide, go to the doctor promptly. Additionally, buying semaglutide with high quality from a reliable supplier, like AASraw, is crucial.
Dosage and Administration of Semaglutide for Reference
The dosage and administration of semaglutide can vary depending on the indication for use. Here are some general guidelines:
①Indication: Type 2 Diabetes Mellitus
· Subcutaneous Injection
Week 1-4:0.25 mg/week
Week 5 and onward:0.5 mg/week
√ If needed, after at least 4 weeks on the 0.5-mg dose, increase to 1 mg subcutaneously once weekly.
√ If needed, after at least 4 weeks on the 1-mg dose, increase to 2 mg subcutaneously once weekly; do not exceed 2 mg/week.
· Oral Tablet
Day 1-30:3 mg/day
Day 31 and onward:7 mg/day
√ If needed, after at least 30 days on the 7-mg dose, increase to 14 mg orally once daily.
√ Note: Do not take two 7-mg tablets to achieve a 14-mg dose
②Indication: Chronic Weight Management
· Subcutaneous Injection
Week 1-4:0.25 mg/week
Week 5-8:0.5 mg/week
Week 9-12:1 mg/week
Week 13-16:1.7 mg/week
Week 17 and onward:2.4 mg/week (maintenance dose)
√ Initiate with a low dose and gradually escalate to a maintenance dose to minimize gastrointestinal adverse reactions.
√ If unable to tolerate a dose during escalation, consider delaying dose escalation for 4 weeks.
√ If unable to tolerate the maintenance dose of 2.4 mg once weekly, may temporarily decrease to 1.7 mg once weekly for a maximum of 4 weeks; after 4 weeks, increase back to maintenance 2.4 mg once weekly; discontinue if not tolerated after the second attempt.
√ Note: The dosage and administration of semaglutide may vary depending on the indication for use. Follow the instructions provided by your doctor or as indicated on the medication label. Moreover, try your best to buy pure semaglutide to achieve the best efficacy.
Where to buy Semaglutide？
Semaglutide, a highly sought-after medication for the treatment of type 2 diabetes, has become increasingly popular among patients seeking effective solutions to manage their condition. As a result, online marketplaces have emerged as a convenient platform for people to buy semaglutide online. These digital platforms provide customers with the opportunity to compare prices, read reviews, and access a wide range of options to suit their needs. However, it is essential for customers to exercise caution when purchasing semaglutide online, as counterfeit or low-quality products could potentially compromise their health. By conducting thorough research and selecting a reputable and certified seller, individuals can confidently purchase semaglutide online and effectively manage their diabetes with ease.
AASraw aiming to manufacture and supply chemical intermediates and active pharmaceutical ingredients (APIs), is a trusted provider of high-quality semaglutide and other related products. Their commitment to rigorous quality control and adherence to industry standards ensures that customers receive only the best products for their health and well-being. By shopping at AASraw, individuals seeking semaglutide can enjoy a convenient, secure, and reliable purchasing experience, all while benefiting from their extensive knowledge and expertise in the field.
Semaglutide Testing Report-HNMR
What is HNMR and What does HNMR spectrum tell you? H Nuclear Magnetic Resonance (NMR) spectroscopy is an analytical chemistry technique used in quality control and research for determining the content and purity of a sample as well as its molecular structure. For example, NMR can quantitatively analyze mixtures containing known compounds. For unknown compounds, NMR can either be used to match against spectral libraries or to infer the basic structure directly. Once the basic structure is known, NMR can be used to determine molecular conformation in solution as well as studying physical properties at the molecular level such as conformational exchange, phase changes, solubility, and diffusion.
How to buy Semaglutide from AASraw?
❶To contact us by our email inquiry system, or leave your WhatsApp number to us, our customer service representative(CSR) will contact you in 12 hours.
❷To provide us with your inquired quantity and address.
❸Our CSR will provide you with the quotation, payment term, tracking number, delivery ways, and estimated arrival date(ETA).
❹Payment done and the goods will be sent out in 12 hours.
❺Goods received and give comments.
 Ghusn W,De la Rosa A,Sacoto D,Cifuentes L,Campos A,Feris F,Hurtado MD,Acosta A.Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.JAMA Netw Open.2022 Sep 1;5(9):e2231982.
 Wilding JPH,Batterham RL,Davies M,Van Gaal LF,Kandler K,Konakli K,Lingvay I,McGowan BM,Oral TK,Rosenstock J,Wadden TA,Wharton S,Yokote K,Kushner RF; STEP 1 Study Group.Weight regain and cardiometabolic effects after withdrawal of semaglutide:The STEP 1 trial extension.Diabetes Obes Metab.2022 Aug;24(8):1553-1564.
 Garvey WT,Batterham RL,Bhatta M,Buscemi S,Christensen LN,Frias JP,Jódar E,Kandler K,Rigas G,Wadden TA,Wharton S; STEP 5 Study Group.Two-year effects of semaglutide in adults with overweight or obesity:the STEP 5 trial.Nat Med.2022 Oct;28(10):2083-2091.
 Knudsen LB,Lau J.The Discovery and Development of Liraglutide and Semaglutide.Front Endocrinol (Lausanne).2019 Apr 12;10:155.
 Mahapatra MK,Karuppasamy M,Sahoo BM.Therapeutic Potential of Semaglutide,a Newer GLP-1 Receptor Agonist,in Abating Obesity,Non-Alcoholic Steatohepatitis and Neurodegenerative diseases:A Narrative Review.Pharm Res.2022 Jun;39(6):1233-1248.